ZIRCON Ph III Imaging Study - Positive Top-Line Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Q3 2022 Business Update to accompany quarterly results
- Appendix 4C and Activities Report - September 2022 Quarter
- TLX250-CDx Indication Expansion - Preliminary Data
- Expansion of partnership with GE Healthcare in PET imaging
- Health Canada Approves Illuccix for Prostate Cancer Imaging
Later from Telix Pharmaceuticals
- ZIRCON Ph III Imaging Study - Top-Line data presentation
- Telix Acquires Optimal Tracers
- ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU
- Webcast link correction - JP Morgan Conference Presentation
- Appendix 4C and Activities Report - December 2022 Quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals